AIFF Firefly Neuroscience, Inc.
USTechnologyAs of 2026-07-08 16:00
Why AIFF matters now
Firefly Neuroscience, Inc. (AIFF) is a US stock in Technology. The latest InvestLog snapshot shows $1.22 with -3.17% on the session and $19.0M in market capitalization; recent performance reads 1-month -17.47% and YTD +56.57%.
The latest financial table shown here is Q1 2026, with revenue of $485.0K, net income of $-2.0M, and EPS of $-0.13. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -36.6%.
The latest indexable market news headline is "Firefly's AI-Driven Evoke System Powers Discovery of Novel Electrophysiological Biomarker for PTSD" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is available with a median target of $—; recent insider activity includes Lipschitz Gregory filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.63
P/S
13.47
EV/EBITDA
-2.09
DCF Value
$-0.15
FCF Yield
-36.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
52.0%
Operating Margin
-539.8%
Net Margin
-565.4%
ROE
-94.7%
ROA
-82.1%
ROIC
-101.1%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $485.0K | $-2.0M | $-0.13 |
| Q4 2025 | $412.0K | $-2.5M | $-0.20 |
| FY 2025 | $1.1M | $-19.9M | $-1.82 |
| Q3 2025 | $388.0K | $-2.6M | $-0.20 |
Analyst Ratings
Consensus
—
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Technology
Industry
Software - Application
Country
CA
Exchange
—
Beta
0.53
Based in Toronto, Canada, Firefly Neuroscience, Inc. is a medical technology and artificial intelligence firm specializing in developing neuroscientific solutions. The company's primary goal is to enhance patient outcomes for individuals affected by mental illnesses and neurological disorders. Its flagship product, Brain Network Analytics, is a sophisticated software platform engineered to aid in the diagnosis and treatment of a diverse range of cognitive and psychiatric conditions. These conditions encompass, but are not limited to, depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder. Firefly Neuroscience, Inc. caters to both pharmaceutical companies and medical practitioners.